After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...

The FDA has taken umbrage with certain Incyte promotional claims related to its chronic graft-versus-host disease (cGVHD) ...

The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Retinal diseases are among the fastest growing causes of blindness, having a profound impact on patients’ independence and ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...

MOGAD, or myelin oligodendrocyte glycoprotein antibody-associated disease, is a rare disease in which the immune system ...

While the scale of the currency headwinds in Roche’s first-quarter financial update caught many off guard, the company’s ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...